Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCS Subpoena Focuses On Period Of Lilly Ownership, Advance Paradigm Says

Executive Summary

A Justice Department/HHS Inspector General investigation of PCS is focusing on the period when the pharmacy benefit management company was owned by Lilly, Advance Paradigm maintains.

You may also be interested in...



FTC Review Of Caremark Deal Will Be Fourth Look At PCS

FTC's review of the Caremark/AdvancePCS merger will be the agency's fourth look at the PCS pharmacy benefit management business in less than a decade - but the first time the agency has considered a straightforward horizontal merger among independent, stand-alone PBMs

FTC Review Of Caremark Deal Will Be Fourth Look At PCS

FTC's review of the Caremark/AdvancePCS merger will be the agency's fourth look at the PCS pharmacy benefit management business in less than a decade - but the first time the agency has considered a straightforward horizontal merger among independent, stand-alone PBMs

Clinical Trial Recruitment By Physicians May Receive Prosecutorial Attention

Clinical trial recruitment by physician practices could come under closer scrutiny by federal prosecutors, Philadelphia Assistant U.S. Attorney James Sheehan suggested at the National Congress on Health Care Compliance Feb. 7 in Washington, D.C

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel